Overview

MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)

Status:
Completed
Trial end date:
1996-09-01
Target enrollment:
Participant gender:
Summary
A study to compare rizatriptan (MK0462) 5 mg by mouth (p.o.) and sumatriptan 50 mg p.o. for the acute treatment of a migraine attack.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Rizatriptan
Sumatriptan